- TG Therapeutics press release (NASDAQ:TGTX): Q1 GAAP EPS of $0.03 misses by $0.14.
- Revenue of $120.86M (+90.4% Y/Y) beats by $3M.
-
2025 Financial Guidance
- Raises BRIUMVI U.S. net product revenue target to $560 million for the full year 2025 (prior guidance of $525 million for
TG Therapeutics GAAP EPS of $0.03 misses by $0.14, revenue of $120.86M beats by $3M
